These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23929174)

  • 1. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Clinicoecon Outcomes Res; 2013; 5():611-21. PubMed ID: 24348057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy.
    Mencacci C; Di Sciascio G; Katz P; Ripellino C
    Clinicoecon Outcomes Res; 2013; 5():87-99. PubMed ID: 23413176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
    J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
    Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
    Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
    Leelahanaj T
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.
    Perlis RH; Patrick A; Smoller JW; Wang PS
    Neuropsychopharmacology; 2009 Sep; 34(10):2227-36. PubMed ID: 19494805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M; Iskedjian M; Ruiz IA; Einarson TR
    Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
    Alrasheed M; Hincapie AL; Guo JJ
    J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
    Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
    Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
    Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression and pain: an appraisal of cost effectiveness and cost utility of antidepressants.
    Pan YJ; Pan CH; Chan HY; Kuo KH
    J Psychiatr Res; 2015 Apr; 63():123-31. PubMed ID: 25727051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of depression with and without headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants.
    Pan YJ; Kuo KH; Wang SJ
    J Affect Disord; 2015 Jan; 170():255-65. PubMed ID: 25261631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
    Nguyen KH; Gordon LG
    Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.